Clinical Outcome and Toxicity Profiles of Patients with EGFR-mutation Positive Non-Small-Cell Lung Cancer

被引：0
|
作者：
Munawar, K. [1 ]
Sheikh, H. [1 ]
机构：
[1] Shaukat Khanum Mem Canc Hosp, Lahore, Pakistan
来源：
JOURNAL OF THORACIC ONCOLOGY | 2021年 / 16卷 / 03期
关键词：
EGFR mutation; EGFR-TKI; Lung cancer;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P76.75
引用
收藏
页码：S621 / S622
页数：2
相关论文
共 50 条
  • [1] Role of osimertinib in the treatment of EGFR-mutation positive non-small-cell lung cancer
    Carlisle, Jennifer W.
    Ramalingam, Suresh S.
    [J]. FUTURE ONCOLOGY, 2019, 15 (08) : 805 - 816
  • [2] Characteristics and outcomes of patients with EGFR-mutation positive non-small-cell lung cancer receiving gefitinib beyond radiological progression
    Hosomi, Yukio
    Tanai, Chiharu
    Yoh, Kiyotaka
    Goto, Yasushi
    Sakai, Hiroshi
    Kato, Terufumi
    Kaburagi, Takayuki
    Nishio, Makoto
    Kim, Young Hak
    Inoue, Akira
    Hasegawa, Yoshinori
    Isobe, Hiroshi
    Tomizawa, Yoshio
    Mori, Yoshiaki
    Minato, Koichi
    Yamada, Kazuhiko
    Ohashi, Yasuo
    Kunitoh, Hideo
    [J]. EXPERT OPINION ON PHARMACOTHERAPY, 2018, 19 (10) : 1049 - 1056
  • [3] Clinical outcome of treatment with pemetrexed/cisplatin in patients with EGFR-mutation negative (EGFR-) metastatic non-small cell lung cancer (NSCLC)
    Storozhakova, Anna E.
    Vladimirova, Liubov Yu
    Kit, Oleg Ivanovich
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [4] Efficacy of osimertinib in patients with EGFR-mutation positive non-small cell lung cancer with malignant pleural effusion
    Kiritani, Ayu
    Amino, Yoshiaki
    Uchibori, Ken
    Akita, Takahiro
    Harutani, Yuhei
    Ogusu, Shinsuke
    Tsugitomi, Ryosuke
    Manabe, Ryo
    Ariyasu, Ryo
    Kitazono, Satoru
    Yanagitani, Noriko
    Nishio, Makoto
    [J]. THORACIC CANCER, 2024, 15 (05) : 402 - 409
  • [5] Financial consequences of a payment-by-results scheme in Catalonia: gefitinib in advanced EGFR-mutation positive non-small-cell lung cancer
    Clopes, Ana
    Gasol, Montse
    Cajal, Rosana
    Segu, Luis
    Crespo, Ricard
    Mora, Ramon
    Simon, Susana
    Cordero, Luis A.
    Calle, Candela
    Gilabert, Antoni
    Germa, Josep R.
    [J]. JOURNAL OF MEDICAL ECONOMICS, 2017, 20 (01) : 1 - 7
  • [6] Cancer Stem Cell Biomarkers in EGFR-Mutation-Positive Non-Small-Cell Lung Cancer
    Codony-Servat, Jordi
    Codony-Servat, Caries
    Cardona, Andres Felipe
    Gimenez-Capitan, Ana
    Drozdowskyj, Ana
    Berenguer, Ordi
    Paulina Bracht, Milan Wilhe Mina
    Ito, Masaoki
    Karachaliou, Niki
    Rosell, Rafael
    [J]. CLINICAL LUNG CANCER, 2019, 20 (03) : 167 - 177
  • [7] Nivolumab in non-small-cell lung cancer with EGFR mutation
    Yoshida, H.
    Kim, Y. H.
    Ozasa, H.
    Nagai, H.
    Sakamori, Y.
    Tsuji, T.
    Nomizo, T.
    Yasuda, Y.
    Funazo, T.
    Hirai, T.
    [J]. ANNALS OF ONCOLOGY, 2018, 29 (03) : 777 - 778
  • [8] EGFR mutation analysis in non-small-cell lung cancer
    Tapia, C.
    Savic, S.
    Bihl, M.
    Rufle, A.
    Zlobec, I.
    Terracciano, L.
    Bubendorf, L.
    [J]. PATHOLOGE, 2009, 30 (05): : 384 - 392
  • [9] Targeting PKCι-PAK1 in EGFR-mutation positive non-small cell lung cancer
    Ito, Masaoki
    Codony-Servat, Cartes
    Karachaliou, Niki
    Rosell, Rafael
    [J]. TRANSLATIONAL LUNG CANCER RESEARCH, 2019, 8 (05) : 667 - +
  • [10] Predictive value of CD73 expression in EGFR-mutation positive non-small-cell lung cancer patients received immune checkpoint inhibitors.
    Ishii, Hidenobu
    Azuma, Koichi
    Kinoshita, Takashi
    Matsuo, Norikazu
    Naito, Yoshiko
    Tokito, Takaaki
    Yamada, Kazuhiko
    Hoshino, Tomoaki
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
12345